Insights

Gene Therapy Expertise Decibel Therapeutics specializes in gene therapies for hearing and balance disorders, offering potential collaboration opportunities for companies in the biotechnology and pharmaceutical sectors looking to advance precision medicine solutions in this area.

Recent Mergers and Partnerships Decibel Therapeutics' recent merger with Regeneron and partnership agreements indicate a strong focus on expanding capabilities and reaching new markets, presenting an opportunity for strategic alliances and synergies with complementary organizations.

Proprietary Platform Integration By integrating single-cell genomics, bioinformatic analyses, and precision gene therapy technologies, Decibel Therapeutics has developed a unique platform that may interest companies seeking innovative technologies and research tools for advancing treatments in the biotechnology space.

Global Clinical Trials With the launch of CHORD, a Phase I/II global clinical trial for gene therapy, Decibel Therapeutics offers potential partnership opportunities for companies interested in participating in cutting-edge research and clinical development programs related to hearing and balance disorders.

Experienced Board Members The addition of Kevin F. McLaughlin to Decibel Therapeutics' Board of Directors brings valuable expertise to the company, signaling a focus on leadership and strategic guidance that may attract investors and partners looking for a well-supported biotechnology venture.

Decibel Therapeutics Tech Stack

Decibel Therapeutics uses 8 technology products and services including Google Analytics, WordPress, Drupal, and more. Explore Decibel Therapeutics's tech stack below.

  • Google Analytics
    Analytics
  • WordPress
    Content Management System
  • Drupal
    Content Management System
  • MySQL
    Database
  • Font Awesome
    Font Scripts
  • Google Font API
    Font Scripts
  • WP Featherlight
    Web Platform Extensions
  • Nginx
    Web Servers

Media & News

Decibel Therapeutics's Email Address Formats

Decibel Therapeutics uses at least 1 format(s):
Decibel Therapeutics Email FormatsExamplePercentage
FLast@decibeltx.comJDoe@decibeltx.com
97%
F.Last@decibeltx.comJ.Doe@decibeltx.com
1%
FMiddleLast@decibeltx.comJMichaelDoe@decibeltx.com
1%
Last@decibeltx.comDoe@decibeltx.com
1%

Frequently Asked Questions

Where is Decibel Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Decibel Therapeutics's main headquarters is located at 1325 Boylston Street Suite 500 Boston, MA 02215 US. The company has employees across 2 continents, including North AmericaAsia.

What is Decibel Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Decibel Therapeutics's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Decibel Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Decibel Therapeutics is a publicly traded company; the company's stock symbol is DBTX.

What is Decibel Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Decibel Therapeutics's official website is decibeltx.com and has social profiles on LinkedIn.

How much revenue does Decibel Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2024, Decibel Therapeutics's annual revenue reached $35M.

What is Decibel Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Decibel Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Decibel Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2024, Decibel Therapeutics has approximately 51 employees across 2 continents, including North AmericaAsia. Key team members include Chief Medical Officer: P. W.VP Pharmacology: A. S.Vice President Quality Assurance: E. M.. Explore Decibel Therapeutics's employee directory with LeadIQ.

What industry does Decibel Therapeutics belong to?

Minus sign iconPlus sign icon
Decibel Therapeutics operates in the Biotechnology Research industry.

What technology does Decibel Therapeutics use?

Minus sign iconPlus sign icon
Decibel Therapeutics's tech stack includes Google AnalyticsWordPressDrupalMySQLFont AwesomeGoogle Font APIWP FeatherlightNginx.

What is Decibel Therapeutics's email format?

Minus sign iconPlus sign icon
Decibel Therapeutics's email format typically follows the pattern of . Find more Decibel Therapeutics email formats with LeadIQ.

How much funding has Decibel Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2024, Decibel Therapeutics has raised $82M in funding. The last funding round occurred on Nov 09, 2020 for $82M.
Decibel Therapeutics

Decibel Therapeutics

Biotechnology ResearchMassachusetts, United States51-200 Employees

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of building a world of connection for people with hearing and balance disorders.

Guidelines: https://bit.ly/3IzmNvU

Section iconCompany Overview

Headquarters
1325 Boylston Street Suite 500 Boston, MA 02215 US
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
DBTX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
51-200

Section iconFunding & Financials

  • $82M

    Decibel Therapeutics has raised a total of $82M of funding over 5 rounds. Their latest funding round was raised on Nov 09, 2020 in the amount of $82M.

  • $10M$50M

    Decibel Therapeutics's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $82M

    Decibel Therapeutics has raised a total of $82M of funding over 5 rounds. Their latest funding round was raised on Nov 09, 2020 in the amount of $82M.

  • $10M$50M

    Decibel Therapeutics's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.